Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2025 ,inter alia, to consider and approve 1. Un-audited Financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical Ltd has informed BSE that its Board of Directors will meet on Friday, 07 November 2025 at the company's corporate office. The key item on the agenda is the approval of unaudited financial results for the quarter and half year ended 30 September 2025 (Q2 FY26 and H1 FY26). The board will also take on record the Limited Review Report from the auditors for the quarter ended 30 September 2025. Any other business may be taken up with the Chair's permission. The intimation has been filed under SEBI LODR Regulations 29 and 33.
No direct impact on shareholders — this is a routine pre-results intimation. Investors should watch the actual numbers when results are announced on or after 07 November 2025 for any surprises on revenue, margins, or profitability.